AstraZeneca will utilise the Bina GMS[1] to support its development work across its main therapeutic areas of respiratory, inflammation and autoimmunity, cardiovascular and metabolic disease, and oncology.
Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximise the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support genomic data analysis and management. Bina will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
Dr. Carl Barrett, Vice President, Translational Oncology, at AstraZeneca, said: “Bina GMS is a powerful data analysis platform that will help AstraZeneca leverage more effectively genomic data across all phases of our research globally as we develop personalised therapies to treat complex diseases.”
Justin Johnson, Principal Translational Genomic Scientist at AstraZeneca, added: “In working with Bina, we can not only significantly accelerate the speed in which we incorporate genomic data into areas like target discovery and patient selection, but we can do this on top of a flexible, scalable and validated analysis infrastructure that our bench scientists can work with.” Johnson will be presenting early results of the collaboration during the Cambridge Healthtech Institute’s 14th Annual Bio-IT World Conference and Expo (Bio-IT) in Boston, MA on Thursday 23 April.
“We are very excited about the work we are doing with the AstraZeneca team,” said Dr. Narges Bani Asadi, CEO and Founder of Bina. “In this collaboration, our multidisciplinary team of scientists and engineers will try to push the boundaries of genomics research. We are very fortunate to be able to contribute to the research at AstraZeneca. Through this collaboration we both hope to define a new standard for the pharmaceutical research industry in how to effectively leverage the genomic information for discovery and development.”
[1] Bina products are for research use only and not for use in diagnostic procedures
About Bina Technologies
Bina Technologies builds next-generation technologies for scalable, accurate processing and management of genomic information. Bina’s Genomic Management Solution is a comprehensive analysis platform used by clinical and translational researchers to gain insight from their genomic data sets. Bina’s Genomic Management Solution dramatically decreases the complexity, time, and cost of genomic analysis, accelerating the science of personalised medicine. Bina Technologies was acquired by Roche in December, 2014. Learn more about Bina’s product, technologies and team at www.bina.com
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com